Beatty Laboratory

First-line Metastatic Pancreatic Cancer

• A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer

• Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma (REVOLUTION)

• Paricalcitol plus gemcitabine and nab-paclitaxel in metastatic pancreatic cancer

Second-line Metastatic Pancreatic Cancer

• A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer

• A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies

Third-line Metastatic Pancreatic Cancer

• View potential clinical trial opportunities

First-line Maintenance Metastatic

• Phase 1b study of soluble beta glucan (odetiglucan) in combination with CD40 agonist (CDX-1140)

• Testing the addition of pembrolizumab, an immunotherapy cancer drug to olaparib alone as therapy for patients with pancreatic cancer that has spread with inherited BRCA mutations

Localized Unresectable Pancreatic Cancer

• A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer

Localized Resectable Pancreatic Cancer

• View potential clinical trial opportunities

Adjuvant Therapy after Surgical Resection of Pancreatic Cancer

• DC Vaccine in Pancreatic Cancer

• A Randomized Study of Olaparib or Placebo in Patients With Surgically Removed Pancreatic Cancer Who Have a BRCA1, BRCA2 or PALB2 Mutation, The APOLLO Trial